Biogen BIIB 132

Today, Biogen made the decision to stop the MERA study for Spinocerebellar Ataxia type 3. This decision was made after careful assessment of the nonclinical safety data, clinical pharmacodynamic data, and future development of BIIB132. For more information, you can visit Pharma News - National Ataxia Foundation

NAF is disappointed to have to announce this news but we are hopeful for the future of other treatments in the pipeline. You can find our full treatment pipeline here: Pipeline - National Ataxia Foundation